TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance

Yang, Yinmeng; Kohler, M. Eric; Chien, Christopher D.; Sauter, Christopher T.; Jacoby, Elad; Yan, Chunhua; Hu, Ying; Wanhainen, Kelsey; Qin, Haiying; Fry, Terry J.

doi:10.1126/scitranslmed.aag1209

Cited by 208CAR-T cell therapy researchT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance

Open access

Yang, Yinmeng, Kohler, M. Eric, Chien, Christopher D., Sauter, Christopher T., Jacoby, Elad, Yan, Chunhua, Hu, Ying, Wanhainen, Kelsey +2 more·2017·Science Translational Medicine

DOI 10.1126/scitranslmed.aag1209PMC PMC6944272

Open this paper in CoChat — free account

Abstract

TCR engagement induces CD8 CAR T cell exhaustion and poor in vivo functionality in mice.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.aag1209

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Tumor rejection that depends on CD4+ Th cells and NK cells but not on CD8+ T cell activity has been observed.
“However, tumor rejection that depends on CD4+ Th cells and NK cells but not on CD8+ T cell activity has been observed213–215.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [213]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · see citing works
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · see citing works
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898 · see citing works
Self-citation
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,484 · see citing works
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112 · see citing works
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103 · see citing works
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595 · see citing works
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells
Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D., Marić, I., Stetler‐Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2011) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,441 · see citing works
The basic principles of chimeric antigen receptor (CAR) design
Sadelain, M., Brentjens, R., & Rivière, I. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0548 · Cited by 1,423 · see citing works
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.006 · Cited by 1,355 · see citing works
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
Pulè, M. A., Savoldo, B., Myers, G. D., Rössig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., et al. (2008) · Nature Medicine · doi:10.1038/nm.1882 · Cited by 1,195 · see citing works
Acute Lymphoblastic Leukemia
Pui, C., Relling, M. V., & Downing, J. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmra023001 · Cited by 1,182 · see citing works
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
Gardner, R., Finney, O. C., Annesley, C., Brakke, H., Summers, C. N., Leger, K. J., Bleakley, M., Brown, C., Mgebroff, S., Kelly‐Spratt, K. S., et al. (2017) · Blood · doi:10.1182/blood-2017-02-769208 · Cited by 1,124 · see citing works
Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 <sup>+</sup> and CD4 <sup>+</sup> CD19-specific chimeric antigen receptor–modified T cells
Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf8621 · Cited by 1,016 · see citing works
Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo
Sommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2015) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 864 · see citing works
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
Kochenderfer, J. N., Dudley, M. E., Carpenter, R. O., Kassim, S. H., Rose, J. J., Telford, W. G., Hakim, F. T., Halverson, D. C., Fowler, D. H., Hardy, N. M., et al. (2013) · Blood · doi:10.1182/blood-2013-08-519413 · Cited by 589 · see citing works
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study
Cruz, C. C., Micklethwaite, K. P., Savoldo, B., Ramos, C. A., Lam, S., Ku, S., Diouf, O., Liu, E., Barrett, A. J., Ito, S., et al. (2013) · Blood · doi:10.1182/blood-2013-06-506741 · Cited by 508 · see citing works
Molecular and Transcriptional Basis of CD4+ T Cell Dysfunction during Chronic Infection
Crawford, A., Angelosanto, J., Kao, C., Doering, T. A., Odorizzi, P. M., Barnett, B. E., & Wherry, E. J. (2014) · Immunity · doi:10.1016/j.immuni.2014.01.005 · Cited by 495 · see citing works
Mechanisms maintaining peripheral tolerance
Mueller, D. L. (2009) · Nature Immunology · doi:10.1038/ni.1817 · Cited by 461 · see citing works
CD4 cells can be more efficient at tumor rejection than CD8 cells
Pérez‐Díez, A., Joncker, N. T., Choi, K., Chan, W. F. N., Anderson, C. C., Lantz, O. J., & Matzinger, P. (2007) · Blood · doi:10.1182/blood-2006-10-051318 · Cited by 436 · see citing works
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells
Kochenderfer, J. N., Yu, Z., Frasheri, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Blood · doi:10.1182/blood-2010-01-265041 · Cited by 392 · see citing works
Chimeric Antigen Receptor Therapy for Cancer
Barrett, D. M., Singh, N., Porter, D. L., Grupp, S. A., & June, C. H. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-060512-150254 · Cited by 350 · see citing works
T cell exhaustion during persistent viral infections
Kahan, S. M., Wherry, E. J., & Zajac, A. J. (2015) · Virology · doi:10.1016/j.virol.2014.12.033 · Cited by 321 · see citing works
Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy
Maus, M. V., & June, C. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1433 · Cited by 269 · see citing works
The Optimal Antigen Response of Chimeric Antigen Receptors Harboring the CD3ζ Transmembrane Domain Is Dependent upon Incorporation of the Receptor into the Endogenous TCR/CD3 Complex
Bridgeman, J. S., Hawkins, R. E., Bagley, S., Blaylock, M. G., Holland, M., & Gilham, D. E. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901766 · Cited by 267 · see citing works
The self-obsession of T cells: how TCR signaling thresholds affect fate 'decisions' and effector function
Hogquist, K. A., & Jameson, S. C. (2014) · Nature Immunology · doi:10.1038/ni.2938 · Cited by 265 · see citing works
Cross-primed CD8+ T cells mediate graft rejection via a distinct effector pathway
Valujskikh, A., Lantz, O., Celli, S., Matzinger, P., & Heeger, P. (2002) · Nature Immunology · doi:10.1038/ni831 · Cited by 234 · see citing works
Intrinsic Functional Dysregulation of CD4 T Cells Occurs Rapidly following Persistent Viral Infection
Brooks, D. G., Teyton, L., Oldstone, M. B. A., & McGavern, D. B. (2005) · Journal of Virology · doi:10.1128/jvi.79.16.10514-10527.2005 · Cited by 229 · see citing works
Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity
Ghosh, A., Smith, M. M., James, S. E., Davila, M. L., Velardi, E., Argyropoulos, K. V., Gunset, G., Perna, F., Kreines, F. M., Levy, E. R., et al. (2017) · Nature Medicine · doi:10.1038/nm.4258 · Cited by 219 · see citing works
Epstein-Barr virus–specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy
Rössig, C., Bollard, C. M., Nuchtern, J. G., et al. (2002) · Blood · doi:10.1182/blood.v99.6.2009 · Cited by 203 · see citing works
Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells
Terakura, S., Yamamoto, T. N., Gardner, R., Turtle, C. J., Jensen, M. C., & Riddell, S. R. (2011) · Blood · doi:10.1182/blood-2011-07-366419 · Cited by 196 · see citing works
Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells
Chmielewski, M. M., Hombach, A. A., & Abken, H. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00371 · Cited by 168 · see citing works
Reprogramming of antiviral T cells prevents inactivation and restores T cell activity during persistent viral infection
Brooks, D. G. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26856 · Cited by 141 · see citing works
How I treat acute lymphoblastic leukemia in older adolescents and young adults
Curran, E. K., & Stock, W. (2015) · Blood · doi:10.1182/blood-2014-11-551481 · Cited by 124 · see citing works
Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation
Lee, D. W., Stetler‐Stevenson, M., Yuan, C. M., Shah, N. N., Delbrook, C., Yates, B., Zhang, H., Zhang, L., Kochenderfer, J. N., Rosenberg, S. A., et al. (2016) · Blood · doi:10.1182/blood.v128.22.218.218 · Cited by 122 · see citing works
Self-citation
Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD
Jacoby, E., Yang, Y., Qin, H., Chien, C. D., Kochenderfer, J. N., & Fry, T. J. (2015) · Blood · doi:10.1182/blood-2015-08-664250 · Cited by 114 · see citing works
Self-citation
Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
Maude, S. L., Barrett, D. M., Rheingold, S. R., Aplenc, R., Teachey, D. T., Callahan, C. A., Baniewicz, D., White, C., Talekar, M. K., Shaw, P. A., et al. (2016) · Blood · doi:10.1182/blood.v128.22.217.217 · Cited by 76 · see citing works
Early regulation of CD8 T cell alloreactivity by CD4+CD25– T cells in recipients of anti‐CD154 antibody and allogeneic BMT is followed by rapid peripheral deletion of donor‐reactive CD8+ T cells, precluding a role for sustained regulation
Fehr, T. H., Takeuchi, Y., Kurtz, J. M., et al. (2005) · European Journal of Immunology · doi:10.1002/eji.200526190 · Cited by 74 · see citing works
High incidence of proviral integrations in the Hoxa locus in a new model of E2a–PBX1-induced B-cell leukemiaPreprint
Bijl, J. J., Sauvageau, M., Thompson, A., et al. (2005) · Genes & Development · doi:10.1101/gad.1268505 · Cited by 64 · see citing works
CD19CAR T Cell Products of Defined CD4:CD8 Composition and Transgene Expression Show Prolonged Persistence and Durable MRD-Negative Remission in Pediatric and Young Adult B-Cell ALL
Gardner, R., Finney, O. C., Smithers, H. M., Leger, K. J., Annesley, C., Summers, C. N., Brown, C., Mgebroff, S., Lindgren, C. G., Spratt, K., et al. (2016) · Blood · doi:10.1182/blood.v128.22.219.219 · Cited by 40 · see citing works
Biology of Childhood Acute Lymphoblastic Leukemia
Nigro, L. L. (2013) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e31828f8746 · Cited by 38 · see citing works
Donor-Derived Anti-CD19 Chimeric-Antigen-Receptor-Expressing T Cells Cause Regression Of Malignancy Persisting After Allogeneic Hematopoietic Stem Cell Transplantation
Kochenderfer, J. N., Dudley, M. E., Carpenter, R. O., et al. (2013) · Blood · doi:10.1182/blood.v122.21.151.151 · Cited by 10 · see citing works
Minor Antigen Distribution Predicts Site-Specific Graft-versus-Tumor Activity of Adoptively Transferred, Minor Antigen-Specific CD8 T Cells
Shand, J. C., Qin, H., Nasholm, N. M., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.10.009 · Cited by 10 · see citing works
Self-citation

Flagged first, then by citations

Sorted by citations

TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944 · see citing works
Immunosenescence: a key player in cancer development
Lian, J., Yue, Y., Yu, W., & Zhang, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00986-z · Cited by 510 · see citing works
Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity
Wang, D., Aguilar, B., Starr, R., Alizadeh, D., Brito, A., Sarkissian, A., Ostberg, J. R., Forman, S. J., & Brown, C. E. (2018) · JCI Insight · doi:10.1172/jci.insight.99048 · Cited by 233 · see citing works
T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy
Yamamoto, T. N., Lee, P.-H., Vodnala, S. K., Gurusamy, D., Kishton, R. J., Yu, Z., Eidizadeh, A., Eil, R., Fioravanti, J., Gattinoni, L., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci121491 · Cited by 156 · see citing works
Self-citation
Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies.
Cheng, J., Zhao, L., Zhang, Y., Qin, Y., Guan, Y., Zhang, T., Liu, C., & Zhou, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01237 · Cited by 153 · see citing works
GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
Park, J. A., & Cheung, N.-K. V. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01012-y · Cited by 88 · see citing works
Engineering better chimeric antigen receptor T cells
Zhang, H., Zhao, P., & Huang, H. (2020) · Experimental Hematology & Oncology · doi:10.1186/s40164-020-00190-2 · Cited by 93 · see citing works
Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy
Tipanee, J., Samara-Kuko, E., Gevaert, T., Chuah, M. K., & VandenDriessche, T. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.06.006 · Cited by 76 · see citing works
Histone deacetylases 1 and 2 restrain CD4+ cytotoxic T lymphocyte differentiation
Preglej, T., Hamminger, P., Luu, M., Bulat, T., Andersen, L., Göschl, L., Stolz, V., Rica, R., Sandner, L., Waltenberger, D., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133393 · Cited by 36 · see citing works
Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer
Saillard, M., Cenerenti, M., Romero, P., & Jandus, C. (2021) · Vaccines · doi:10.3390/vaccines9050454 · Cited by 23 · see citing works

Superantigen-mediated deletion of specific T cell receptor V β subsets in the SCID-hu Thy/Liv mouse is induced by staphylococcal enterotoxin B, but not HIV-1
Komanduri, K. V., Salha, M.-D., Sékaly, R. P., et al. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.2.544 · Cited by 16 · see citing works
Impact of early expression of TCR α chain on thymocyte development
Huang, C., & Kanagawa, O. (2004) · European Journal of Immunology · doi:10.1002/eji.200424870 · Cited by 17 · see citing works
The degree of CD8 dependence of cytolytic T cell precursors is determined by the nature of the T cell receptor (TCR) and influences negative selection in TCR‐transgenic mice
Auphan‐Anezin, N., Curnow, J., Guimezanes, A., et al. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240718 · Cited by 47 · see citing works
The origin of CD4−CD8−TCRαβ+ thymocytes: a model based on T-cell receptor avidity
Budd, R. C., & Mixter, P. F. (1995) · Immunology Today · doi:10.1016/0167-5699(95)80019-0 · Cited by 43 · see citing works
TCR repertoire intratumor heterogeneity of CD4+ and CD8+ T cells in centers and margins of localized lung adenocarcinomas
Zhang, C., Ding, H., Huang, H., Palashati, H., Miao, Y., Xiong, H., & Lu, Z. (2018) · International Journal of Cancer · doi:10.1002/ijc.31760 · Cited by 42 · see citing works

Authors: Yang, Y., Kohler, M. E., Chien, C. D., Sauter, C. T., Jacoby, E., Yan, C., Hu, Y., Wanhainen, K., Qin, H., & Fry, T. J.
Affiliations: National Institutes of Health (US)
Corresponding author: Fry, Terry J.
ORCID: Yang, Yinmeng
Kohler, M. Eric
Chien, Christopher D.
Sauter, Christopher T.
Jacoby, Elad
Yan, Chunhua
Hu, Ying
Wanhainen, Kelsey
Qin, Haiying
Fry, Terry J.
Venue: Science Translational Medicine
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2017-11-22
Volume: 9
Issue: 417
ISSN: 1946-6234 (ISSN-L)
1946-6242
DOI: 10.1126/scitranslmed.aag1209
PMC: PMC6944272
OpenAlex: W2768550677
Cited by: 208
References: 43
Citations by year: 2026: 11 · 2025: 29 · 2024: 27 · 2023: 18 · 2022: 25 · 2021: 25 · 2020: 34 · 2019: 22 · 2018: 16 · 2017: 1
FWCI: 8.80
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Science Translational Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (award349764)
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: chimeric antigen receptor T cells, T cell receptor engagement, CD8+ T cells, CD4+ T cells, T cell exhaustion, apoptosis, pre-B acute lymphoblastic leukemia, CAR-T cell expansion, T cell signaling, relapsed/refractory B-cell malignancies
MeSH terms: Animals, Cell Line, Female, Flow Cytometry, Lymphocyte Activation, Mice, Inbred C57BL, Receptors, Antigen, Receptors, Antigen, T-Cell, CD4-Positive T-Lymphocytes, Apoptosis, CD8-Positive T-Lymphocytes, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks